ATR:NYE-AptarGroup Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 140.15

Change

-0.17 (-0.12)%

Market Cap

USD 4.78B

Volume

0.42M

Analyst Target

USD 125.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AptarGroup, Inc., is a solution provider of packaging delivery solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

-1.68 (-1.54%)

USD 98.67B
BDX Becton Dickinson and Company

-5.67 (-2.36%)

USD 69.44B
ALC Alcon AG

+1.15 (+1.47%)

USD 38.68B
HYB New America High Income Closed..

+0.06 (+0.77%)

USD 35.93B
RMD ResMed Inc

-1.17 (-0.54%)

USD 27.76B
WST West Pharmaceutical Services I..

-3.44 (-0.93%)

USD 27.24B
BAX Baxter International Inc

-0.02 (-0.05%)

USD 18.81B
TFX Teleflex Incorporated

+4.28 (+2.15%)

USD 10.10B
STVN Stevanato Group SpA

-0.36 (-1.34%)

USD 7.29B
BLCO Bausch + Lomb Corp

-0.26 (-1.88%)

USD 4.87B

ETFs Containing ATR

FCUL:CA 0.00 % 0.00 %

N/A

N/A
XMLV Invesco S&P MidCap Low Vo.. 0.00 % 0.25 %

+0.34 (+0.62%)

USD 0.78B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.37% 94% A 88% B+
Dividend Return 0.33% 50% F 18% F
Total Return 13.70% 94% A 87% B+
Trailing 12 Months  
Capital Gain 18.70% 89% A- 71% C-
Dividend Return 1.36% 56% F 17% F
Total Return 20.06% 89% A- 69% C-
Trailing 5 Years  
Capital Gain 28.05% 64% D 64% D
Dividend Return 6.88% 43% F 23% F
Total Return 34.93% 64% D 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.12% 44% F 56% F
Dividend Return 5.40% 44% F 52% F
Total Return 1.27% 56% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 19.50% 78% C+ 57% F
Risk Adjusted Return 27.67% 56% F 51% F
Market Capitalization 4.78B 61% D- 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.10 73% 20%
Price/Book Ratio 3.94 50% 22%
Price / Cash Flow Ratio 16.14 53% 22%
Price/Free Cash Flow Ratio 15.12 65% 25%
Management Effectiveness  
Return on Equity 12.95% 71% 67%
Return on Invested Capital 9.39% 76% 63%
Return on Assets 6.51% 78% 80%
Debt to Equity Ratio 29.53% 69% 73%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector